Akari Therapeutics (AKTX) Non Operating Income (2014 - 2026)
Akari Therapeutics (AKTX) reported Non Operating Income of $444000.0 for Q1 2026, up 346.67% on a YoY basis from $99403.0 in Q1 2025, and up 122.36% sequentially from -$2.0 million in Q4 2025.
Akari Therapeutics (AKTX) Non Operating Income (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of Non Operating Income data on file, last reported at $444000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 346.67% year-over-year to $444000.0; the trailing twelve-month figure through Mar 2026 stood at -$402000.0 (down 132.19% YoY), and the FY2025 full-year result was -$1.0 million, down 155.4% from the prior year.
- Non Operating Income climbed to $444000.0 in Q1 2026, from -$2.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $5.6 million in Q1 2023 to a low of -$2.0 million in Q4 2025.
- A 4-year average of $620615.4 and a median of $423000.0 in 2024 frame the typical range for Non Operating Income.
- Peak annual rise in Non Operating Income reached 1222.94% in 2025, while the deepest fall reached 362.5% in 2025.
- Tracing AKTX's Non Operating Income over 4 years: stood at $952000.0 in 2023, then surged by 58.19% to $1.5 million in 2024, then plunged by 231.87% to -$2.0 million in 2025, then jumped by 122.36% to $444000.0 in 2026.
- Business Quant data shows AKTX's Non Operating Income at $444000.0 in Q1 2026, -$2.0 million in Q4 2025, and -$84000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -46.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 444,000.00 |
| Dec 31, 2025 | -1.99 Mn |
| Sep 30, 2025 | -84,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | -180,000.00 |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | -109,000.00 |
| Mar 31, 2024 | 423,000.00 |
| Dec 31, 2023 | 952,000.00 |
| Sep 30, 2023 | -364,000.00 |
| Jun 30, 2023 | 615,000.00 |
| Mar 31, 2023 | 5.60 Mn |
| Dec 31, 2020 | 85,659.00 |
| Sep 30, 2020 | 1.16 Mn |
| Jun 30, 2020 | -1.53 Mn |
| Mar 31, 2020 | 1.18 Mn |
| Dec 31, 2019 | -3,710.00 |
| Sep 30, 2019 | 235,426.00 |
| Jun 30, 2019 | 83,674.00 |